Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New findings from S. Dipalma and co-authors in the area of breast cancer published
July 10th, 2008
"Chromogenic in situ hybridisation (CISH) is an alternative to immunohistochemistry or FISH for the assessment of HER2 oncogene status in breast cancer. Although CISH is being used increasingly in routine diagnostics, there are no established inter-laboratory quality assurance programmes for this test," scientists in the United Kingdom report. "The reproducibility of HER2 CISH analysis was assessed when performed by seven different centres that use the test routinely in diagnostic service. The results from 28 cases showed overall concordance of 98.5% (192/195 tests; k coefficient 0.91). One of the discrepancies was due to the invasive carcinoma having been cut out in...
Source: Women's Health Weekly (2008-07-10)
|
